ET
ETBI.US Eastgate Biotech Corp
- Market cap
- USD 5.29M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2017.
Is ETBI.US undervalued?
Graham numberThe Graham number of Eastgate Biotech Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eastgate Biotech Corp fundamental analysis
No fundamental analysis for Eastgate Biotech Corp yet.
Eastgate Biotech Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eastgate Biotech Corp
Eastgate Biotech Corp., produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The company is developing pharmaceutical products, such as Lorazepam spray for acute seizures; and EGP-1214, intraoral (sublingual) insulin tablet for diabetes and metabolic syndrome. It is also developing natural healing medication and other products, including E-drops NANO, a plant essential oil for urinary and vaginal tract infections; Es…
Full company profileEastgate Biotech Corp financial statements
2017 annualized: Fiscal year 2017 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2017, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eastgate Biotech Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 132K | 0.00 | 184K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 113K | 0.00 | -15.5K |
| Operating Income | -606K | -1.66M | -4.82M | -4.17M | -2.63M | -4.14M |
| Net Income | -623K | -1.72M | -4.91M | -4.28M | -2.98M | -4.40M |
| Balance Sheet | ||||||
| Total Assets | 105K | 71.8K | 483K | 298K | 0.00 | 1.67M |
| Total Liabilities | 714K | 2.40M | 1.88M | 2.78M | 4.62M | 6.96M |
| Shareholders' Equity | -609K | -2.33M | -1.40M | -2.48M | -4.62M | -5.29M |
| Cash & Short-term Investments | 100K | 458.00 | 286K | 19.2K | 0.00 | 4.91K |
| Cash Flow | ||||||
| Operating Cash Flow | -408K | -408K | -1.24M | -568K | -389K | -2.11M |
| Capital Expenditure | 22.3K | 22.3K | 99.8K | 0.00 | 0.00 | 207K |
| Ratios | ||||||
| ROA | -596.0% | -2,397.5% | -1,016.2% | -1,437.1% | - | -263.4% |
| Net Profit Margin | - | - | - | -3,242.8% | - | -2,397.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Eastgate Biotech Corp dividends
Eastgate Biotech Corp has not paid dividends in the last 5 fiscal years.
Who owns Eastgate Biotech Corp
Ownership data of Eastgate Biotech Corp is not available yet.
Eastgate Biotech Corp company profile
- Company name
- Eastgate Biotech Corp
- Ticker
- ETBI.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 65 Harbour Square, Toronto, ON, Canada, M5J 2L4
- Phone
- 647-692-0652
- Website
- EastGateBiotech.com
About Eastgate Biotech Corp
Eastgate Biotech Corp., produces and distributes nutraceuticals that are based on natural therapies and absorbed naturally by the body. The company is developing pharmaceutical products, such as Lorazepam spray for acute seizures; and EGP-1214, intraoral (sublingual) insulin tablet for diabetes and metabolic syndrome. It is also developing natural healing medication and other products, including E-drops NANO, a plant essential oil for urinary and vaginal tract infections; Essential, a Vitamin D3, to improve the body's digestive, cardiovascular, and immune systems; GluCora to lower daily intake of insulin; VCleanzz, an antibacterial wash for fruits and vegetables; Cleanezze, a natural hand sanitizer; and Warts X, a natural herbal product to treats warts. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was incorporated in 1999 and is based in Toronto, Canada.
Eastgate Biotech Corp management
3- Ms. Rosella C. PerriCEO, Secretary, Treasurer & Director · born 1968
- Mr. William D. AbajianVice Chairman, President & COO · born 1958
- Dr. Joseph Schwarz Ph.D.Chief Scientific Officer · born 1956